Based on these results, on May 10, 2019, the US FDA approved ramucirumab for treatment of HCC patients for patients who have been previously treated with sorafenib and have an AFP of ≥ 400 ng/mL. This evidence concerns the gene AFP and hepatocellular carcinoma.